Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells

Journal of Cellular Physiology

Volumn 207, Issue 1, 2006, Pages 158-164

  Secchiero, Paola ^a   Corallini, Federica ^a   Barbarotto, Elisa ^a   Melloni, Elisabetta ^a   Di Iasio, Maria Grazia ^a   Tiribelli, Mario ^b   Zauli, Giorgio ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD30 ANTIGEN; CD40 LIGAND; CHLORAMBUCIL; DNA; FLUDARABINE; INTERLEUKIN 8; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DNA MICROARRAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMOGENESIS; PATHOGENESIS; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARRIER PROTEINS; CELL SURVIVAL; CHLORAMBUCIL; FLOW CYTOMETRY; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-1; INTERLEUKIN-8; LEUKEMIA, B-CELL, CHRONIC; MEMBRANE GLYCOPROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; UP-REGULATION; VIDARABINE;

EID: 33644899159     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20547     Document Type: Article

References (29)

1. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. 1997. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179.
2. Bharti AC, Aggarwal BB. 2004. Ranking the role of RANK ligand in apoptosis. Apoptosis 9:677-690.
3. Biagi E, Dotti G, Yvon E, Lee E, Pule M, Vigouroux S, Gottschalk S, Popat U, Rousseau R, Brenner M. 2005. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood 105:2436-2442.
4. Di Celle PF, Carbone A, Marchis D, Zhou D, Sozzani S, Zupo S, Pini M, Mantovani A, Foa R. 1994. Cytokine gene expression in B-cell chronic lymphocytic leukemia: Evidence of constitutive interleukin-8 (IL-8) mRNA expression and secretion of biologically active IL-8 protein. Blood 84:220-228.
5. Di Celle PF, Mariani S, Riera L, Stacchini A, Reato G, Carbone A, Foa R. 1996. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonged survival in an autocrine fashion. Blood 87:4382-4389.
6. Dighiero G, Binet JL. 2000. When and how to treat chronic lymphocytic leukemia. N Engl J Med 343:1799-1801.
7. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J. 1999. RANK is essential for osteoclast and lymph node development. Genes Dev 13:2412-2418.
8. Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillenwater AM, Cabanillas F, Aggarwal BB, Younes A. 2001. Functional expression of receptor activator of nuclear factor kB in Hodgkin disease cell lines. Blood 98:2784-2790.
9. Horie R, Gattei V, Ito K, Imajo-Ohmi S, Tange T, Miyauchi J, Pinto A, Degan M, De Iuliis A, Tassan Mazzocco F, Rossi FM, Higashihara M, Watanabe T. 1999. Frequent expression of the variant CD30 in human malignant myeloid and lymphoid neoplasms. Am J Pathol 155:2029-2041.
10. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. 1999. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540-3545.
11. Josien R, Wong BR, Li HL, Steinman RM, Choi Y. 1999. TRANCE, a tumor necrosis factor family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 162:2562-2568.
12. Josien R, Li HL, Ingulli E, Sarma S, Wong BR, Vologodskaia M, Steinman RM, Choi Y. 2000. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 191: 495-502.
13. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. 1992. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258:1780-1798.
14. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM. 1999. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323.
15. Langstein J, Schwarz H. 1999. Human 4-1BB induces the expression of M-CSF in peripheral blood mononuclear cells. J Leukoc Biol 65:829-833.
16. Molica S. 2001. Angiogenesis in B-cell chronic lymphocytic leukemia: Methods of study, clinical significance and prognostic implications. Leuk Lymphoma 42:603-607.
17. Molica S, Vitelly G, Levato D, Levato L, Dattilo A, Gandolfo GM. 1999. Clinicobiological implications of increased serum levels of interleukin-8 in B-cell chronic lymphocytic leukemia. Hematologica 84:208-211.
18. Muller I, Pfister SM, Grohs U, Zweigner J, Handgretinger R, Niethammer RD, Bruchelt G. 2003. Receptor activator of nuclear factor -kB ligand plays a nonredundant role in doxorubicin-induced apoptosis. Cancer Res 63:1772-1775.
19. Munk Pedersen I, Reed J. 2004. Microenvironmental interactions and survival of CLL B-cells. Leuk Lymphoma 45:2365-2372.
20. Packham G, Stevenson FK. 2005. Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 114:441-449.
21. Reed JC, Kitada S, Kim Y, Byrd J. 2002. Modulating apoptosis pathways in low-grade B-cell malignancies using biological response modifiers. Semin Oncol 29:10-24.
22. Saito K, Ohara N, Hotokezaka H, Fukumoto S, Yuasa K, Naito M, Fujiwara T, Nakayama K. 2004. Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and its inhibitory effect on M-CSF/RANKL-induced in vitro osteoclastogenesis. J Biol Chem 279:13555-13563.
23. Secchiero P, Tiribelli M, Barbarotto E, Celeghini C, Michelutti A, Masolini P, Fanin R, Zauli G. 2005. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. J Cell Physiol 205:246-252.
24. Till KJ, Zuzel M, Cawley JC. 1999. The role of hyaluronan and interleukin 8 in the migration of chronic lymphocytic leukemia cells within lymphoreticular tissues. Cancer Res 59:4419-4426.
25. von Bergwelt-Baildon M, Maecker B, Schultze J, Gribben JG. 2004. CD40 activation: Potential for specific immunotherapy in B-CLL. Ann Oncol 15:853-857.
26. Watts DA, Hunt NH, Wanigasekara Y, Bloomfield G, Wallach D, Roufogalis BD, Chaudhri G. 1999. A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in reverse signaling. EMBO J 18:2119-2126.
27. Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O'Brien S, Giles FJ, Kantarjian H, Thomas D, Faderl S, Lerner S, Keating M, Albitar M. 2003. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol 120:452-456.
28. Wolowiec D, Wozniak Z, Potoczek S, Ganczarski G, Wrobel T, Kuliczkowski K, Frydecka I, Jelen M. 2004. Bone marrow angiogenesis and proliferation in B-cell chronic lymphocytic leukemia. Anal Quant Cytol Histol 26:263-270.
29. Wong BR, Josien R, Choi Y. 1999. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol 65:715-724.